comparemela.com

Latest Breaking News On - Vicore pharma holding ab - Page 2 : comparemela.com

Vicore announces first human dosed with novel ATRAG, C106

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2.

Uppsala lanVastra gotalands lanCarl johan dalsgaardPrnewswire vicore pharma holdingVicore pharma holdingJohan dalsgaardPharma holdingVicore pharma holding ab

Vicore strengthens rare lung disease pipeline with PAH indication

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2.

United kingdomCity ofVastra gotalands lanVicore pharmaGerry coghlanChris dentonCarl johan dalsgaardUniversity college londonRoyal free national pulmonary hypertension serviceNational pulmonary hypertension physicians associationPrnewswire vicore pharma holdingVicore pharma holdingCentre for rheumatologyProfessor chris dentonJoint directorRoyal free hospital

Vicore strengthens rare lung disease pipeline with PAH indication

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2.

United kingdomCity ofVastra gotalands lanVicore pharmaGerry coghlanChris dentonCarl johan dalsgaardUniversity college londonRoyal free national pulmonary hypertension serviceNational pulmonary hypertension physicians associationPrnewswire vicore pharma holdingVicore pharma holdingCentre for rheumatologyProfessor chris dentonJoint directorRoyal free hospital

Vicore to host R&D Day

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2.

United statesUnited kingdomVastra gotalands lanUniversity of southern californiaLos angelesCity ofVicore pharmaToby maherMaureen hortonGerry coghlanUniversity college londonJohns hopkins universityNational cardiac dublinNational pulmonary hypertension physicians associationRegional health authorityUniversity college dublin

Vicore takes major step towards a clinical platform company targeting AT2R - new molecule ready for phase 1

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2.

Vastra gotalands lanVicore pharmaCarl johan dalsgaardVicore pharma holdingJohan dalsgaardPharma holdingVicore pharma holding ab

vimarsana © 2020. All Rights Reserved.